Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

Published:2021-10-22 Issue: Volume: Page:
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Kiguchi Toru^ORCID,Yamaguchi Masaki,Takezako Naoki,Miyawaki Shuichi,Masui Koichi,Ihara Yuichiro,Hirota Masao,Shimofurutani Naoko,Naoe Tomoki

Funder

Otsuka Pharmaceutical Co., Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-021-03074-4.pdf

Reference43 articles.

1. Ferrara F (2014) Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia? Hematol Oncol 32(1):1–9. https://doi.org/10.1002/hon.2046

2. Przespolewski A, Szeles A, Wang ES (2018) Advances in immunotherapy for acute myeloid leukemia. Future Oncol 14(10):963–978. https://doi.org/10.2217/fon-2017-0459

3. Beyar-Katz O, Gill S (2018) Novel approaches to acute myeloid leukemia immunotherapy. Clin Cancer Res 24(22):5502–5515. https://doi.org/10.1158/1078-0432.CCR-17-3016

4. Call KM et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60:509–520. https://doi.org/10.1016/0092-8674(90)90601-a

5. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA (1990) Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343(6260):774–778. https://doi.org/10.1038/343774a0

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wilms’ tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives;Human Vaccines & Immunotherapeutics;2023-12-26

2. Wilms’ tumor gene 1 in hematological malignancies: friend or foe?;Hematology;2023-09-05

3. Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide;Cancer Immunology, Immunotherapy;2023-04-24